AbbVie announced the launch of Creon (pancrelipase) 36,000 lipase-unit delayed-release capsules for the treatment of patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. This new strength is the highest dose of pancreatic enzyme replacement therapy (PERT) currently available on the market.
The pancreatic enzymes in Creon catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.
Creon is already available in 3,000 lipase-unit; 6,000 lipase-unit; 12,000 lipase-unit, and 24,000 lipase-unit delayed-release capsules.
The new Creon capsules contain 36,000 units of lipase; 114,000 units of protease; and 180,000 units of amylase. It is available in 100- and 250-count bottles.
For more information call (800) 633-9110 or visit Creon.com.